{"id":"pem-only","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While specific mechanistic details for 'Pem' from Asan Medical Center are limited in public literature, peptide-based therapeutics in Phase 3 development typically work by activating T-cell responses against tumor-associated antigens or modulating immune checkpoint pathways. The exact molecular target and mechanism require confirmation from clinical trial protocols.","oneSentence":"Pem is a peptide-based immunotherapy that enhances anti-tumor immune responses, likely through peptide vaccine or checkpoint modulation mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:48:10.999Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication not publicly confirmed)"}]},"trialDetails":[{"nctId":"NCT02015104","phase":"PHASE2","title":"Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-12-18","conditions":"Bladder Cancer","enrollment":32},{"nctId":"NCT07017959","phase":"NA","title":"Impact of a Human Origin Heat Inactivated Probiotic-Lactobacillus Paracasei D3.5 (LpD3.5) as Dietary Supplement on Gut Mucin and Intestinal Permeability in Adults With IBD","status":"NOT_YET_RECRUITING","sponsor":"University of South Florida","startDate":"2025-06-15","conditions":"Inflammatory Bowel Diseases","enrollment":15},{"nctId":"NCT03723928","phase":"NA","title":"S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2018-09-17","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative","enrollment":739},{"nctId":"NCT05830812","phase":"","title":"Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2023-01-01","conditions":"Lung Adenocarcinoma, Stage I","enrollment":3000},{"nctId":"NCT06070467","phase":"","title":"Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2024-07-17","conditions":"Eye Diseases, Severe Loss of Vision, Blindness","enrollment":154},{"nctId":"NCT06429891","phase":"NA","title":"Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization","status":"RECRUITING","sponsor":"Hua Zhu","startDate":"2024-08-20","conditions":"Solid Tumor","enrollment":50},{"nctId":"NCT05986981","phase":"PHASE2","title":"MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-08","conditions":"Solid Tumor, Adult","enrollment":20},{"nctId":"NCT04695847","phase":"PHASE1","title":"M1231 in Participants With Solid Tumors","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2021-01-13","conditions":"Metastatic Solid Tumors, Esophageal Cancer, Non-Small Cell Lung Cancer","enrollment":23},{"nctId":"NCT05911555","phase":"","title":"Mucin Levels in Dry Eye and Normal Populations","status":"COMPLETED","sponsor":"ORA, Inc.","startDate":"2013-05","conditions":"Dry Eye","enrollment":34},{"nctId":"NCT02261389","phase":"NA","title":"Follow-up of Early Breast Cancer by Dynamic Evaluation of CEA and CA 15.3 Followed by 18FDG-PET","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2014-09","conditions":"Breast Cancer","enrollment":1507},{"nctId":"NCT02426489","phase":"NA","title":"Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System","status":"TERMINATED","sponsor":"Weinberg Medical Physics LLC","startDate":"2015-07-01","conditions":"Breast Cancer","enrollment":1},{"nctId":"NCT02544880","phase":"PHASE1","title":"PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC","status":"COMPLETED","sponsor":"Donald T. Weed, MD, FACS","startDate":"2016-04-25","conditions":"Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":16},{"nctId":"NCT00928421","phase":"PHASE2","title":"An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2009-06","conditions":"Varicose Veins","enrollment":16},{"nctId":"NCT01428076","phase":"PHASE1","title":"Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2011-08","conditions":"Varicose Veins","enrollment":21},{"nctId":"NCT04441606","phase":"NA","title":"The Role of 68Ga-FAPI-04 PET/CT as a Problem Solving Imaging Modality in Various Malignancies","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2020-06-11","conditions":"Different Types of Cancer","enrollment":50},{"nctId":"NCT03747523","phase":"EARLY_PHASE1","title":"Pilot Study: The Effect of Ergocalciferol on Plasma Mucin-1 Levels","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-03-12","conditions":"Ergocalciferol","enrollment":44},{"nctId":"NCT04565496","phase":"PHASE2","title":"Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer Patients","status":"UNKNOWN","sponsor":"IRCCS San Raffaele","startDate":"2021-01-01","conditions":"Prostate Cancer","enrollment":59},{"nctId":"NCT02725918","phase":"PHASE2","title":"Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2016-04-01","conditions":"Non-small Cell Lung Cancer","enrollment":150},{"nctId":"NCT04153734","phase":"PHASE2","title":"Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Kobe Minimally Invasive Cancer Center","startDate":"2019-12-01","conditions":"Locally Advanced Non-small Cell Lung Cancer","enrollment":21},{"nctId":"NCT01437319","phase":"PHASE1, PHASE2","title":"Mucin Balls and Corneal Inflammation Events","status":"COMPLETED","sponsor":"Johnson & Johnson Vision Care, Inc.","startDate":"2011-09","conditions":"Corneal Inflammation, Corneal Infiltrative Events","enrollment":289},{"nctId":"NCT01613430","phase":"NA","title":"Evaluating Coaches of Older Adults for Cancer Care and Health Behaviors","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2012-06","conditions":"Colorectal Cancer, Breast Cancer, Cervical Cancer","enrollment":1106},{"nctId":"NCT03222466","phase":"NA","title":"Patient Educational Materials for Prostate Cancer Screening","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2017-10-06","conditions":"Patient Educational Materials","enrollment":573},{"nctId":"NCT03101397","phase":"","title":"The Clinical Value of Serum KL-6 Changes on Evaluating Disease Development in Different Diffuse Parenchymal Lung Disease","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2013-02","conditions":"Diffuse Parenchymal Lung Disease","enrollment":180},{"nctId":"NCT03050437","phase":"PHASE2","title":"A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2013-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":96},{"nctId":"NCT01249157","phase":"NA","title":"Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-11","conditions":"Breast Cancer","enrollment":6},{"nctId":"NCT02392143","phase":"NA","title":"Promoting CRC Screening in an Urban Minority Population","status":"COMPLETED","sponsor":"Teachers College, Columbia University","startDate":"2009-01","conditions":"Colorectal Cancer","enrollment":564},{"nctId":"NCT00179309","phase":"PHASE2","title":"Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-09","conditions":"Breast Cancer","enrollment":48},{"nctId":"NCT01757119","phase":"PHASE1","title":"Ferrous Sulphate Supplement in Women With Iron Deficiency Anaemia","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2013-01","conditions":"Iron Deficiency Anemia","enrollment":55},{"nctId":"NCT01593293","phase":"PHASE3","title":"Pemetrexed With or Without Carboplatin for Elderly Non-squamous Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2012-03","conditions":"Non-small Cell Lung Cancer","enrollment":266},{"nctId":"NCT00687778","phase":"","title":"11C-Acetate PET/CT Non-FDG-Avid Tumors","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2008-05","conditions":"Soft Tissue Sarcomas, Thyroid Cancer, Lung Cancer","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Alimta: brand name of pemetrexed"],"phase":"phase_3","status":"active","brandName":"Pem only","genericName":"Pem only","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pem is a peptide-based immunotherapy that enhances anti-tumor immune responses, likely through peptide vaccine or checkpoint modulation mechanisms. Used for Cancer (specific indication not publicly confirmed).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}